137 related articles for article (PubMed ID: 9316650)
1. Effects of fenretinide (4-HPR) on prostate LNCaP cell growth, apoptosis, and prostate-specific gene expression.
Hsieh TC; Wu JM
Prostate; 1997 Oct; 33(2):97-104. PubMed ID: 9316650
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic studies of the effects of the retinoid N-(4-hydroxyphenyl)retinamide on prostate cancer cell growth and apoptosis.
Shen JC; Wang TT; Chang S; Hursting SD
Mol Carcinog; 1999 Mar; 24(3):160-8. PubMed ID: 10204800
[TBL] [Abstract][Full Text] [Related]
3. Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative.
Gao M; Ossowski L; Ferrari AC
J Cell Physiol; 1999 Jun; 179(3):336-46. PubMed ID: 10228952
[TBL] [Abstract][Full Text] [Related]
4. The synthetic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR) exerts antiproliferative and apoptosis-inducing effects in the androgen-independent human prostatic JCA-1 cells.
Hsieh TC; Ng C; Wu JM
Biochem Mol Biol Int; 1995 Oct; 37(3):499-506. PubMed ID: 8595390
[TBL] [Abstract][Full Text] [Related]
5. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.
Choi HE; Shin JS; Leem DG; Kim SD; Cho WJ; Lee KT
Chem Biol Interact; 2016 Dec; 260():196-207. PubMed ID: 27720946
[TBL] [Abstract][Full Text] [Related]
6. Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines.
Hsieh TC; Wu JM
Exp Cell Res; 1999 May; 249(1):109-15. PubMed ID: 10328958
[TBL] [Abstract][Full Text] [Related]
7. Fenretinide: induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells.
Roberson KM; Penland SN; Padilla GM; Selvan RS; Kim CS; Fine RL; Robertson CN
Cell Growth Differ; 1997 Jan; 8(1):101-11. PubMed ID: 8993839
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.
Kuroda K; Liu H; Kim S; Guo M; Navarro V; Bander NH
Prostate; 2009 Oct; 69(14):1579-85. PubMed ID: 19575420
[TBL] [Abstract][Full Text] [Related]
9. Regulation of androgen receptor (AR) and prostate specific antigen (PSA) expression in the androgen-responsive human prostate LNCaP cells by ethanolic extracts of the Chinese herbal preparation, PC-SPES.
Hsieh T; Chen SS; Wang X; Wu JM
Biochem Mol Biol Int; 1997 Jul; 42(3):535-44. PubMed ID: 9247711
[TBL] [Abstract][Full Text] [Related]
10. Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells.
Gupta S; Afaq F; Mukhtar H
Oncogene; 2002 May; 21(23):3727-38. PubMed ID: 12032841
[TBL] [Abstract][Full Text] [Related]
11. Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts.
Liu CM; Lo YC; Tai MH; Wu BN; Wu WJ; Chou YH; Chai CY; Huang CH; Chen IJ
Prostate; 2009 May; 69(6):610-23. PubMed ID: 19143029
[TBL] [Abstract][Full Text] [Related]
12. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS
Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686
[TBL] [Abstract][Full Text] [Related]
13. Testosterone is a potential augmentor of antioxidant-induced apoptosis in human prostate cancer cells.
Gunawardena K; Murray DK; Meikle AW
Cancer Detect Prev; 2002; 26(2):105-13. PubMed ID: 12102144
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
Chiu FL; Lin JK
Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333
[TBL] [Abstract][Full Text] [Related]
15. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
16. Proliferative and androgenic effects of indirubin derivatives in LNCaP human prostate cancer cells at sub-apoptotic concentrations.
Rivest P; Renaud M; Sanderson JT
Chem Biol Interact; 2011 Feb; 189(3):177-85. PubMed ID: 21111724
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line.
Mizokami A; Gotoh A; Yamada H; Keller ET; Matsumoto T
J Urol; 2000 Sep; 164(3 Pt 1):800-5. PubMed ID: 10953159
[TBL] [Abstract][Full Text] [Related]
18. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model.
Gleave ME; Sato N; Sadar M; Yago V; Bruchovsky N; Sullivan L
J Cell Biochem; 1998 Jun; 69(3):271-81. PubMed ID: 9581866
[TBL] [Abstract][Full Text] [Related]
19. Benzyldihydroxyoctenone, a novel nonsteroidal antiandrogen, shows differential apoptotic induction in prostate cancer cells in response to their androgen responsiveness.
Suh H; Oh HL; Lee CH
J Microbiol Biotechnol; 2011 May; 21(5):540-4. PubMed ID: 21617354
[TBL] [Abstract][Full Text] [Related]
20. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.
Iwasa Y; Mizokami A; Miwa S; Koshida K; Namiki M
Int J Urol; 2007 Mar; 14(3):233-9. PubMed ID: 17430262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
